Skip to content

Investingdeck

Finding The Edge

Tag: Amgen

Posted on November 4, 2021November 4, 2021

Competitive Advantage of Amgen: November Update

View post on imgur.com

The competitive advantage of Amgen, like any other pharma company, lies in its patent. We invite readers to take a look at this issue – deeper.

Continue reading “Competitive Advantage of Amgen: November Update”
Posted on August 16, 2021October 31, 2021

Abbvie Dividend Stock Analysis: Patents Play

In Moat versus growth investing, companies could be classified into growth categories or moat categories. Investors need to be very careful in this field.
AbbVie will wear a new identity after the Allergan acquisition
source: freepik

The biggest issue is of course the patent of Humira which will expire in 2023. If sales of that antirheumatic drug tumble, dividends will consequently follow and make AbbVie’s status as a dividend darling questionable. Here we try to dig deeper and give a detailed perspective about what really happens through our AbbVie dividend stock analysis.

Continue reading “Abbvie Dividend Stock Analysis: Patents Play”

Categories

  • Basic of Investing: Seeing Right
  • Competitive Advantage, Preserving Market Share
  • Decision Making
  • Disruption Stock Checklist
  • Dividend Investing. An Passive Income Approach
  • Financial Analysis, Decoding Financial Report
  • Management Stewardship, It's All About Human
  • Uncategorized

Posts

  • Return on Equity: How the number could lie to you
  • Business Model Canvas of Adobe: The Cloud.
  • Decision-Making: Investing, Business, Career, Life
  • Is Nvidia Stock a Buy or Sell? Biden, Game, Datacenter.
  • Decision-Making to Avoid Mistakes: Misconception
  • Investing Resources is About Us: Your Deck
  • As Usual. Disclaimer.
  • Privacy Policy
  • Terms and Conditions
  • Contact Us. Get Touch with The Deck
Privacy Policy Proudly powered by WordPress